Stephen Krieger, MD, FAAN / Clyde E. Markowitz, MD - Navigating the Evolving Management Paradigm Across Multiple Sclerosis Phenotypes in the Age of Potential Prognostic and Predictive Biomarkers - a podcast by PVI, PeerView Institute for Medical Education
from 2020-05-13T18:00
Go online to PeerView.com/EQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium recently held in West Palm Beach, Florida, leading experts on multiple sclerosis (MS) dive into the latest data on approved and emerging therapies for relapsing and progressive forms of MS and offer practical strategies to improve patient management, treatment selection, and outcomes. In addition to exploring the treatment armamentarium for MS, the panel considers the prognostic and predictive utility of serum neurofilament light chain as an emerging biomarker, including how it may affect disease-modifying treatment selection and sequencing. Upon completion of this activity, participants should be better able to: Apply current data on approved and emerging disease-modifying therapies for the treatment of relapsing forms of MS, Employ recent data related to available and investigational therapies for the treatment of progressive forms of MS, Assess available data on the potential prognostic and predictive utility of serum neurofilament light chain levels in patients with MS, Develop strategies based on clinical phenotypes, goals, preferences, and potential biomarker findings when selecting disease-modifying therapies for patients with MS.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education